Replies to post #185208 on Biotech Values

[Praveen]

Qure Congestive Heart Failure
Congestive heart failure (CHF) is a rapidly progressing and in many cases life-threatening disease affecting 26 million people worldwide. Based on research and development at our recently acquired cardiology gene therapy company InoCard, uniQure is developing a novel gene therapy for the one-time treatment of CHF by selectively restoring cardiac deficiency of the calcium-binding protein S100A1, a master regulator of myocardial function. AAV-S100A1 has proven long-term therapeutic efficacy, safety and reduced mortality in a human-relevant in vivo heart failure model compatible with clinical drug regimens. The first human trial is expected to start in 2016

Appreciate your thoughts on this approach.Thank you